Prot #GS-US-367-1173: A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic

  • Flamm, Steven L (PD/PI)

Project: Research project

Project Details

Effective start/end date1/25/161/25/19


  • PRA Health Sciences (GS-US-367-1173 // GS-US-367-1173)
  • Gilead Sciences, Inc (GS-US-367-1173 // GS-US-367-1173)